Posts Archive

NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma...

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma NCT03338972: Phase 1...

(PRIME) NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) NCT03288493: Phase...

A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or...

NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma A single arm,...

KarMMa bb2121 NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma...

NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors...

NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Phase I Trial of Universal Donor NK Cell Therapy...

CRB-401 NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma Study CRB-401...

NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 This is a...

NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma Open-label, single-center, pilot study to assess the safety and feasibility...

NCT02215967: Phase 1 - Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma Background: - T cells...

NCT01729091: Phase 2: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by...